Subscribe to RSS
DOI: 10.1055/s-0038-1656200
Anticoagulant Protection in Surgery[*]
It forms part of the investigations on blood coagulation for which Dr. Tage Astrup, Biological Institute of the Carlsberg Foundation, receives support from the Josiah Macy Jr. Foundation, New York.Publication History
Publication Date:
05 June 2018 (online)
Summary
An evaluation has been made as to whether it is possible to perform operations on patients with tumors of the lungs and with mitral stenosis when the prothrombin-proconvertin-level is reduced by the use of dicumarol. It has been shown that these operations may be performed without the risk of uncontrollable bleedings when prothrombin and proconvertin are reduced to a therapeutic effective level. The prophylaxis seems to protect the patients against the uncontrollable risk of postoperative thromboembolic accidents. The conditions necessary for performing these operations are: the daily control of the P-P.-level, a reliable method for the determination of prothrombin and proconvertin, a meticulous operative hemostasis and the availability of vitamin Kı.
* This investigation was aided by grants from P. Carl Petersen Foundation, Copenhagen, Denmark.
-
References
- 1 Müllertz S, and Storm O. Anticoagulant therapy with dicumarol maintained during major surgery. Circulation 10: 213 1954;
- 2 Storm O, and Tybjaerg Hansen A. Mitral commissurotomy performed during anticoagulant prophylaxis with dicumarol. Circulation 12: 981 1955;